CALQUENCE is the only licensed 2nd-generation BTKi that offers both continuous or fixed-duration treatment options for eligible 1L CLL patients1-3

CLL continuous therapy

CLL fixed duration therapy

Abbreviations:
1L, first line; BTKi, Bruton’s tyrosine kinase inhibitor; CLL, chronic lymphocytic leukaemia; PFS, progression-free survival.

References:
1. Brown, J et al. N Engl J Med. 2025;392(8):748-762 and supplementary information. 2. Calquence (acalabrutinib)100 mg SmPC – UK. 3. Zanubrutinib 80mg hard capsules SmPC – UK. 

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

November 2025 I GB-69423